EverSource Wealth Advisors LLC Has $147,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

EverSource Wealth Advisors LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,125.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 441 shares of the company’s stock after buying an additional 405 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Medpace were worth $147,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Pallas Capital Advisors LLC lifted its stake in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares during the period. Barclays PLC lifted its position in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after purchasing an additional 844 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $3,098,000. Finally, Loomis Sayles & Co. L P raised its stake in shares of Medpace by 7.2% during the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock worth $68,696,000 after buying an additional 13,880 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.4 %

Shares of MEDP stock opened at $326.34 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The firm has a fifty day moving average of $339.97 and a 200-day moving average of $340.56. The firm has a market capitalization of $9.94 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Separately, Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.